Loading...
XWARPHR
Market cap10mUSD
Dec 23, Last price  
3.68PLN
1D
-4.66%
1Q
-35.66%
Jan 2017
-79.16%
IPO
-84.83%
Name

Pharmena SA

Chart & Performance

D1W1MN
XWAR:PHR chart
P/E
1.42
P/S
4.17
EPS
2.60
Div Yield, %
0.00%
Shrs. gr., 5y
4.84%
Rev. gr., 5y
-5.48%
Revenues
10m
-48.29%
3,809,8466,379,5497,704,3868,778,3819,130,00014,138,00014,129,00017,473,00015,914,00012,511,00013,040,00011,099,0009,933,00015,213,00019,022,0009,837,000
Net income
29m
P
611,360771,541123,730608,997-4,100,000-2,843,000-4,086,000-3,616,000-1,664,000-2,389,000-444,000-9,573,000-6,958,000-4,639,000-1,616,00028,941,000
CFO
33m
+1,715.94%
000666,906-4,054,000-3,836,000-5,751,000-4,175,000-950,000619,0003,613,000-13,146,000-2,243,000-3,225,0001,819,00033,032,000
Dividend
Apr 09, 20240.85 PLN/sh
Earnings
Feb 26, 2025

Profile

Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including skin, hair, and nail care products, as well as dietary supplement for atherosclerosis prophylaxis. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. The company is developing 1-MNA, an anti-atherosclerosis drug which is under phase II clinical trial. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. is a subsidiary of Pelion S.A.
URL
https://www.pharmena.eu/
IPO date
Aug 25, 2008
Employees
24
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
9,837
-48.29%
19,022
25.04%
15,213
53.16%
Cost of revenue
11,869
19,382
18,935
Unusual Expense (Income)
NOPBT
(2,032)
(360)
(3,722)
NOPBT Margin
Operating Taxes
5,908
204
182
Tax Rate
NOPAT
(7,940)
(564)
(3,904)
Net income
28,941
-1,890.90%
(1,616)
-65.16%
(4,639)
-33.33%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
69
316
292
Long-term debt
295
704
1,272
Deferred revenue
(88)
Other long-term liabilities
21
2,207
4,204
Net debt
(21,873)
(45,027)
(4)
Cash flow
Cash from operating activities
33,032
1,819
(3,225)
CAPEX
(314)
(226)
(319)
Cash from investing activities
(3,132)
(219)
(248)
Cash from financing activities
(9,261)
(1,466)
3,214
FCF
(14,383)
3,342
(3,808)
Balance
Cash
22,237
1,592
1,460
Long term investments
44,455
108
Excess cash
21,745
45,096
807
Stockholders' equity
(21,951)
(49,909)
(49,298)
Invested Capital
44,381
45,660
48,575
ROIC
ROCE
8.47%
586.14%
EV
Common stock shares outstanding
11,138
11,138
11,110
Price
7.10
26.79%
5.60
-29.20%
7.91
-12.11%
Market cap
79,078
26.79%
62,371
-29.03%
87,881
-11.11%
EV
56,910
17,042
87,621
EBITDA
(1,707)
201
(3,096)
EV/EBITDA
84.79
Interest
371
722
265
Interest/NOPBT